매사추세츠의 혈액암 임상 시험
혈액암 관련 연구 28개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT03816345Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- MGH, Boston
- University of Massachusetts, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07007312Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT04242095HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06487247A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06697184Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
- Massachusetts General Hospital, Boston
피험자 모집 중초기 1상
18세 ~ 70세 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT07358195Assessing DCog Short for Neurotoxicity in CAR-T
- Beth Israel Deaconess Medical Center, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07403812CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT03328078Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06910969SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton
- Dana-Farber Cancer Instiute - Merrimack Valley, Methuen
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT05375643(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04996875Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT04588922Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT06001788InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Dana Farber Cancer Institute, Boston
피험자 모집 중관찰 연구건강한 지원자 환영
전 연령 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05463796PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Brigham and Women's Hospital, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 4. 업데이트됨 · NCT06665100Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06469307Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
- Tufts Medical Center, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT06652633A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545IVIG for Infection Prevention After CAR-T-Cell Therapy
- Massachusetts General Hospital Cancer Center, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT05952804Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- 외 2개
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 5. 7. 업데이트됨 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Massachusetts General Hospital, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 4. 24. 업데이트됨 · NCT06676852Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 4. 21. 업데이트됨 · NCT05646576A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 2. 5. 업데이트됨 · NCT07148180BMT-CARE: Psychosocial Intervention for Transplant Caregivers
- Massachusetts General Hospital Cancer Center, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2025. 10. 15. 업데이트됨 · NCT06472089Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 4. 15. 업데이트됨 · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
1세 ~ 21세 · 모든 성별 · 2024. 12. 6. 업데이트됨 · NCT05476770ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.